Oxygen-mediated endocytosis in cancer

Journal of Cellular and Molecular Medicine

Volumn 14, Issue 3, 2010, Pages 496-503

  Wang, Yi ^a   Ohh, Michael ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

OXYGEN; PROTEIN TYROSINE KINASE; VON HIPPEL LINDAU PROTEIN;

ANIMAL; ANOXIA; ARTICLE; BIOLOGICAL MODEL; ENDOCYTOSIS; HUMAN; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; ANOXIA; ENDOCYTOSIS; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS; OXYGEN; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 77953488431     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2010.01016.x     Document Type: Article

References (112)

1. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med. 2003, 9:677-84.
2. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer. 2002, 2:38-47.
3. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003, 3:721-32.
4. Harrison L, Blackwell K. Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy. Oncologist. 2004, 9:31-40.
5. Watson PH, Chia SK, Wykoff CC. Carbonic anhydrase XII is a marker of good prognosis in invasive breast carcinoma. Br J Cancer. 2003, 88:1065-70.
6. Chia SK, Wykoff CC, Watson PH. Prognostic significance of a novel hypoxia-regulated marker, carbonic anhydrase IX, in invasive breast carcinoma. J Clin Oncol. 2001, 19:3660-8.
7. Wykoff CC, Beasley N, Watson PH. Expression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breast. Am J Pathol. 2001, 158:1011-9.
8. Hutchison GJ, Valentine HR, Loncaster JA. Hypoxia-inducible factor 1alpha expression as an intrinsic marker of hypoxia: correlation with tumor oxygen, pimonidazole measurements, and outcome in locally advanced carcinoma of the cervix. Clin Cancer Res. 2004, 10:8405-12.
9. Airley RE, Loncaster J, Raleigh JA. GLUT-1 and CAIX as intrinsic markers of hypoxia in carcinoma of the cervix: relationship to pimonidazole binding. Int J Cancer. 2003, 104:85-91.
10. Loncaster JA, Harris AL, Davidson SE. Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res. 2001, 61:6394-9.
11. Giatromanolaki A, Koukourakis MI, Sivridis E. Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. Cancer Res. 2001, 61:7992-8.
12. Barbieri MA, Ramkumar TP, Fernadez-Pol S. Receptor tyrosine kinase signaling and trafficking-paradigms revisited. Curr Top Microbiol Immunol. 2004, 286:1-20.
13. Bergeron JJ, Di Guglielmo GM, Baass PC. Endosomes, receptor tyrosine kinase internalization and signal transduction. Biosci Rep. 1995, 15:411-8.
14. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature. 2001, 411:355-65.
15. Davies M. New diagnostic criteria for diabetes - are they doing what they should. Lancet. 1999, 354:610-1.
16. Pawson T, Raina M, Nash P. Interaction domains: from simple binding events to complex cellular behavior. FEBS Lett. 2002, 513:2-10.
17. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000, 103:211-25.
18. Wang GL, Jiang BH, Rue EA. Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA. 1995, 92:5510-4.
19. Wang GL, Semenza GL. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia. Proc Natl Acad Sci USA. 1993, 90:4304-8.
20. Maynard MA, Qi H, Chung J. Multiple splice variants of the human HIF-3 alpha locus are targets of the von Hippel-Lindau E3 ubiquitin ligase complex. J Biol Chem. 2003, 278:11032-40.
21. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995, 270:1230-7.
22. Maynard MA, Ohh M. The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci. 2007, 64:2170-80.
23. Jiang BH, Agani F, Passaniti A. V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res. 1997, 57:5328-35.
24. Maltepe E, Schmidt JV, Baunoch D. Abnormal angiogenesis and responses to glucose and oxygen deprivation in mice lacking the protein ARNT. Nature. 1997, 386:403-7.
25. Huang LE, Arany Z, Livingston DM. Activation of hypoxia-inducible transcription factor depends primarily upon redox-sensitive stabilization of its alpha subunit. J Biol Chem. 1996, 271:32253-9.
26. Leung SK, Ohh M. Playing tag with HIF: the VHL story. J Biomed Biotechnol. 2002, 2:131-5.
27. Ohh M, Kim WY, Moslehi JJ. An intact NEDD8 pathway is required for Cullin-dependent ubiquitylation in mammalian cells. EMBO Rep. 2002, 3:177-82.
28. Ivan M, Kondo K, Yang H. HIFalpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O2 sensing. Science. 2001, 292:464-8.
29. Ohh M, Park CW, Ivan M. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol. 2000, 2:423-7.
30. Ohh M. Ubiquitin pathway in VHL cancer syndrome. Neoplasia. 2006, 8:623-9.
31. Chun YS, Kim MS, Park JW. Oxygen-dependent and -independent regulation of HIF-1alpha. J Korean Med Sci. 2002, 17:581-8.
32. Wiesener MS, Jurgensen JS, Rosenberger C. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J. 2003, 17:271-3.
33. Rosenberger C, Mandriota S, Jurgensen JS. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J Am Soc Nephrol. 2002, 13:1721-32.
34. Gothie E, Richard DE, Berra E. Identification of alternative spliced variants of human hypoxia-inducible factor-1alpha. J Biol Chem. 2000, 275:6922-7.
35. Lee JW, Bae SH, Jeong JW. Hypoxia-inducible factor (HIF-1)alpha: its protein stability and biological functions. Exp Mol Med. 2004, 36:1-12.
36. Gordan JD, Thompson CB, Simon MC. HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation. Cancer Cell. 2007, 12:108-13.
37. Curti BD. Renal cell carcinoma. JAMA. 2004, 292:97-100.
38. Tanimoto K, Makino Y, Pereira T. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 2000, 19:4298-309.
39. Mellman I. Endocytosis and molecular sorting. Annu Rev Cell Dev Biol. 1996, 12:575-625.
40. Aderem A, Underhill DM. Mechanisms of phagocytosis in macrophages. Annu Rev Immunol. 1999, 17:593-623.
41. Lee H, Sodek KL, Hwang Q. Phagocytosis of collagen by fibroblasts and invasive cancer cells is mediated by MT1-MMP. Biochem Soc Trans. 2007, 35:704-6.
42. Silverstein SC, Steinman RM, Cohn ZA. Endocytosis. Annu Rev Biochem. 1977, 46:669-722.
43. Steinman RM, Mellman IS, Muller WA. Endocytosis and the recycling of plasma membrane. J Cell Biol. 1983, 96:1-27.
44. Ridley A. Molecular switches in metastasis. Nature. 2000, 406:466-7.
45. Schlessinger J. Allosteric regulation of the epidermal growth factor receptor kinase. J Cell Biol. 1986, 103:2067-72.
46. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem. 1987, 56:881-914.
47. Takei K, Yoshida Y, Yamada H. Regulatory mechanisms of dynamin-dependent endocytosis. J Biochem. 2005, 137:243-7.
48. Kirchhausen T. Clathrin adaptors really adapt. Cell. 2002, 109:413-6.
49. Aridor M, Traub LM. Cargo selection in vesicular transport: the making and breaking of a coat. Traffic. 2002, 3:537-46.
50. Traub LM, Bannykh SI, Rodel JE. AP-2-containing clathrin coats assemble on mature lysosomes. J Cell Biol. 1996, 135:1801-14.
51. Wang Q, Zhu F, Wang Z. Identification of EGF receptor C-terminal sequences 1005-1017 and di-leucine motif 1010LL1011 as essential in EGF receptor endocytosis. Exp Cell Res. 2007, 313:3349-63.
52. Ungewickell EJ, Hinrichsen L. Endocytosis: clathrin-mediated membrane budding. Curr Opin Cell Biol. 2007, 19:417-25.
53. Maxfield FR, McGraw TE. Endocytic recycling. Nat Rev Mol Cell Biol. 2004, 5:121-32.
54. Lenferink AE, De Roos AD, Van Vugt MJ. The linear C-terminal regions of epidermal growth factor (EGF) and transforming growth factor-alpha bind to different epitopes on the human EGF receptor. Biochem J 1998, 336 (Pt 1):147-51.
55. Rothman JE. Mechanisms of intracellular protein transport. Nature. 1994, 372:55-63.
56. Valencia A, Chardin P, Wittinghofer A. The ras protein family: evolutionary tree and role of conserved amino acids. Biochemistry. 1991, 30:4637-48.
57. Zerial M, Stenmark H. Rab GTPases in vesicular transport. Curr Opin Cell Biol. 1993, 5:613-20.
58. Korobko EV, Palgova IV, Kiselev SL. Apoptotic cleavage of rabaptin-5-like proteins and a model for rabaptin-5 inactivation in apoptosis. Cell Cycle. 2006, 5:1854-8.
59. Vitale G, Rybin V, Christoforidis S. Distinct Rab-binding domains mediate the interaction of Rabaptin-5 with GTP-bound Rab4 and Rab5. EMBO J. 1998, 17:1941-51.
60. Nielsen E, Christoforidis S, Uttenweiler-Joseph S. Rabenosyn-5, a novel Rab5 effector, is complexed with hVPS45 and recruited to endosomes through a FYVE finger domain. J Cell Biol. 2000, 151:601-12.
61. Mills IG, Jones AT, Clague MJ. Involvement of the endosomal autoantigen EEA1 in homotypic fusion of early endosomes. Curr Biol. 1998, 8:881-4.
62. Yamada E. The fine structure of the gall bladder epithelium of the mouse. J Biophys Biochem Cytol. 1955, 1:445-58.
63. Parton RG, Simons K. The multiple faces of caveolae. Nat Rev Mol Cell Biol. 2007, 8:185-94.
64. Kurzchalia TV, Parton RG. Membrane microdomains and caveolae. Curr Opin Cell Biol. 1999, 11:424-31.
65. Rothberg KG, Heuser JE, Donzell WC. Caveolin, a protein component of caveolae membrane coats. Cell. 1992, 68:673-82.
66. Dupree P, Parton RG, Raposo G. Caveolae and sorting in the trans-Golgi network of epithelial cells. EMBO J. 1993, 12:1597-605.
67. Monier S, Parton RG, Vogel F. VIP21-caveolin, a membrane protein constituent of the caveolar coat, oligomerizes in vivo and in vitro. Mol Biol Cell. 1995, 6:911-27.
68. Razani B, Lisanti MP. Caveolin-deficient mice: insights into caveolar function human disease. J Clin Invest. 2001, 108:1553-61.
69. Pelkmans L, Kartenbeck J, Helenius A. Caveolar endocytosis of simian virus 40 reveals a new two-step vesicular-transport pathway to the ER. Nat Cell Biol. 2001, 3:473-83.
70. Campanero-Rhodes MA, Smith A, Chai W. N-glycolyl GM1 ganglioside as a receptor for simian virus 40. J Virol. 2007, 81:12846-58.
71. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature. 2003, 422:37-44.
72. Mayor S, Pagano RE. Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol. 2007, 8:603-12.
73. Lamaze C, Dujeancourt A, Baba T. Interleukin 2 receptors and detergent-resistant membrane domains define a clathrin-independent endocytic pathway. Mol Cell. 2001, 7:661-71.
74. Sabharanjak S, Sharma P, Parton RG. GPI-anchored proteins are delivered to recycling endosomes via a distinct cdc42-regulated, clathrin-independent pinocytic pathway. Dev Cell. 2002, 2:411-23.
75. Naslavsky N, Weigert R, Donaldson JG. Characterization of a nonclathrin endocytic pathway: membrane cargo and lipid requirements. Mol Biol Cell. 2004, 15:3542-52.
76. Jiang X, Huang F, Marusyk A. Grb2 regulates internalization of EGF receptors through clathrin-coated pits. Mol Biol Cell. 2003, 14:858-70.
77. Lund KA, Opresko LK, Starbuck C. Quantitative analysis of the endocytic system involved in hormone-induced receptor internalization. J Biol Chem. 1990, 265:15713-23.
78. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene. 2000, 19:6550-65.
79. Franovic A, Gunaratnam L, Smith K. Translational up-regulation of the EGFR by tumor hypoxia provides a nonmutational explanation for its overexpression in human cancer. Proc Natl Acad Sci USA. 2007, 104:13092-7.
80. Smith K, Gunaratnam L, Morley M. Silencing of epidermal growth factor receptor suppresses hypoxia-inducible factor-2-driven VHL-/- renal cancer. Cancer Res. 2005, 65:5221-30.
81. Swinson DE, O'Byrne KJ. Interactions between hypoxia and epidermal growth factor receptor in non-small-cell lung cancer. Clin Lung Cancer. 2006, 7:250-6.
82. Phillips RJ, Mestas J, Gharaee-Kermani M. Epidermal growth factor and hypoxia-induced expression of CXC chemokine receptor 4 on non-small cell lung cancer cells is regulated by the phosphatidylinositol 3-kinase/PTEN/AKT/ mammalian target of rapamycin signaling pathway and activation of hypoxia inducible factor-1alpha. J Biol Chem. 2005, 280:22473-81.
83. Swinson DE, Jones JL, Cox G. Hypoxia-inducible factor-1 alpha in non small cell lung cancer: relation to growth factor, protease and apoptosis pathways. Int J Cancer. 2004, 111:43-50.
84. Peng XH, Karna P, Cao Z. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem. 2006, 281:25903-14.
85. Bottaro DP, Liotta LA. Cancer: out of air is not out of action. Nature. 2003, 423:593-5.
86. Michalopoulos GK, DeFrances MC. Liver regeneration. Science. 1997, 276:60-6.
87. Pennacchietti S, Michieli P, Galluzzo M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell. 2003, 3:347-61.
88. Koochekpour S, Jeffers M, Wang PH. The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol. 1999, 19:5902-12.
89. Chen EY, Mazure NM, Cooper JA. Hypoxia activates a platelet-derived growth factor receptor/phosphatidylinositol 3-kinase/Akt pathway that results in glycogen synthase kinase-3 inactivation. Cancer Res. 2001, 61:2429-33.
90. Hsu T, Adereth Y, Kose N. Endocytic function of von Hippel-Lindau tumor suppressor protein regulates surface localization of fibroblast growth factor receptor 1 and cell motility. J Biol Chem. 2006, 281:12069-80.
91. Wang Y, Roche O, Yan MS. Regulation of endocytosis via the oxygen-sensing pathway. Nat Med. 2009, 15:319-24.
92. Goel HL, Languino LR. Integrin signaling in cancer. Cancer Treat Res. 2004, 119:15-31.
93. Mosesson Y, Mills GB, Yarden Y. Derailed endocytosis: an emerging feature of cancer. Nat Rev Cancer. 2008, 8:835-50.
94. Yoon SO, Shin S, Mercurio AM. Hypoxia stimulates carcinoma invasion by stabilizing microtubules and promoting the Rab11 trafficking of the alpha6beta4 integrin. Cancer Res. 2005, 65:2761-9.
95. Caswell PT, Spence HJ, Parsons M. Rab25 associates with alpha5beta1 integrin to promote invasive migration in 3D microenvironments. Dev Cell. 2007, 13:496-510.
96. Cheng KW, Lahad JP, Kuo WL. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med. 2004, 10:1251-6.
97. Sikes RA, Walls AM, Brennen WN. Therapeutic approaches targeting prostate cancer progression using novel voltage-gated ion channel blockers. Clin Prostate Cancer. 2003, 2:181-7.
98. Dada LA, Chandel NS, Ridge KM. Hypoxia-induced endocytosis of Na,K-ATPase in alveolar epithelial cells is mediated by mitochondrial reactive oxygen species and PKC-zeta. J Clin Invest. 2003, 111:1057-64.
99. Dada LA, Novoa E, Lecuona E. Role of the small GTPase RhoA in the hypoxia-induced decrease of plasma membrane Na,K-ATPase in A549 cells. J Cell Sci. 2007, 120:2214-22.
100. Zhou G, Dada LA, Chandel NS. Hypoxia-mediated Na-K-ATPase degradation requires von Hippel Lindau protein. FASEB J. 2008, 22:1335-42.
101. Mobasheri A, Fox R, Evans I. Epithelial Na, K-ATPase expression is down-regulated in canine prostate cancer; a possible consequence of metabolic transformation in the process of prostate malignancy. Cancer Cell Int. 2003, 3:8-17.
102. Sakai H, Suzuki T, Maeda M. Up-regulation of Na(+),K(+)-ATPase alpha 3-isoform and down-regulation of the alpha1-isoform in human colorectal cancer. FEBS Lett. 2004, 563:151-4.
103. Bradham C, McClay DR. p38 MAPK in development and cancer. Cell Cycle. 2006, 5:824-8.
104. Huang CC, You JL, Wu MY. Rap1-induced p38 mitogen-activated protein kinase activation facilitates AMPA receptor trafficking via the GDI.Rab5 complex. Potential role in (S)-3,5-dihydroxyphenylglycene-induced long term depression. J Biol Chem. 2004, 279:12286-92.
105. Mace G, Miaczynska M, Zerial M. Phosphorylation of EEA1 by p38 MAP kinase regulates mu opioid receptor endocytosis. EMBO J. 2005, 24:3235-46.
106. Fratti RA, Backer JM, Gruenberg J. Role of phosphatidylinositol 3-kinase and Rab5 effectors in phagosomal biogenesis and mycobacterial phagosome maturation arrest. J Cell Biol. 2001, 154:631-44.
107. An SS, Pennella CM, Gonnabathula A. Hypoxia alters biophysical properties of endothelial cells via p38 MAPK- and Rho kinase-dependent pathways. Am J Physiol Cell Physiol 2005, 289:C521-30.
108. Lamaze C, Chuang TH, Terlecky LJ. Regulation of receptor-mediated endocytosis by Rho and Rac. Nature. 1996, 382:177-9.
109. Jin HG, Yamashita H, Nagano Y. Hypoxia-induced upregulation of endothelial small G protein RhoA and Rho-kinase/ROCK2 inhibits eNOS expression. Neurosci Lett. 2006, 408:62-7.
110. Turcotte S, Desrosiers RR, Beliveau R. Hypoxia upregulates von Hippel-Lindau tumor-suppressor protein through RhoA-dependent activity in renal cell carcinoma. Am J Physiol Renal Physiol 2004, 286:F338-48.
111. Xue Y, Bi F, Zhang X. Role of Rac1 and Cdc42 in hypoxia induced p53 and von Hippel-Lindau suppression and HIF1alpha activation. Int J Cancer. 2006, 118:2965-72.
112. Williams TM, Lisanti MP. Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol 2005, 288:C494-506.